OR6A2 and aortic atherosclerosis: Inhibition of the OR6A2 (Olfr2) receptor may also have a role against aortic atherosclerosis, vascular wall inflammation and the ECM/VSMC disruption frequently observed in these cases, as relevant studies with OR6A2 (Olfr2)-deficiency show a halt in the progression of aortic dilatation [65,173].